27Jul 2023
USFDA Accepts Application For Boehringer Ingelheim OFEV For Children, Adolescents Aged 6-17 Years Old With Fibrosing Interstitial Lung Disease

USFDA Accepts Application For Boehringer Ingelheim OFEV For Children, Adolescents Aged 6-17 Years Old With Fibrosing Interstitial Lung Disease

Boehringer Ingelheim's sNDA for OF EV (nintedanib) has been accepted by the FDA as a potential treatment for fibrosing interstitial lung disease (ILD) in children and adolescents aged 6 to 17. Childhood ILD often lacks approved therapies, causing a significant burden to patients and families. If approved, OFEV would become the first and only treatment for this age group, offering hope for those suffering from fibrosing ILD.

  • #family health

Like

Save

Share